Evidence map›Paper›PMID 35006488›Full record

ArticleBulletin of experimental biology and medicine2022

Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.

A A Litvin, G B Kolyvanov, P O Bochkov, R V Shevchenko, A L Podol'ko, K N Kolyasnikova, V P Zherdev

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

A A LitvinLaboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia. litbiopharm@yandex.ru.
G B KolyvanovLaboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
P O BochkovLaboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
R V ShevchenkoLaboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
A L Podol'koLaboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
K N KolyasnikovaLaboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
V P ZherdevLaboratory of Pharmacokinetics, V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the pharmacokinetics of GZK-111 (N-phenylacetyl-glycyl-L-proline ethyl ether), a compound with neuroprotective activity, and its metabolite CPG (cyclo-L-prolylglycine) in rat blood plasma after single intravenous and intragastric administration in a dose of 20 mg/kg. It was found that the parent drug undergoes intensive biotransformation; its metabolite CPG persists in the circulation more than twice as long as GZK-111 and its plasma concentrations were higher by 50-70 times than the concentrations of the parent compound.

Indexed as

DipeptidesAnimalsRatsDipeptidescyclo-L-prolylglycineGZK-111HPLCmass spectrometryneuroprotectorpharmacokinetics

Identifiers

PMID35006488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.